DC
IBB icon

Davenport & Co’s iShares Biotechnology ETF IBB Stock Holding History

Davenport & Co’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.62M Sell
45,300
-3,438
-7% -$591K 0.04% 277
2026
Q1 		$8.23M Buy
48,738
+6,310
+15% +$1.08M 0.04% 265
2025
Q4 		$7.16M Buy
42,428
+27,589
+186% +$4.48M 0.04% 277
2025
Q3 		$2.14M Sell
14,839
-779
-5% -$106K 0.01% 513
2025
Q2 		$1.98M Buy
15,618
+869
+6% +$107K 0.01% 514
2025
Q1 		$1.89M Sell
14,749
-7
-0% -$949 0.01% 507
2024
Q4 		$1.95M Sell
14,756
-480
-3% -$67.5K 0.01% 485
2024
Q3 		$2.22M Buy
15,236
+77
+0.5% +$11.1K 0.01% 453
2024
Q2 		$2.08M Buy
15,159
+140
+0.9% +$18.7K 0.01% 448
2024
Q1 		$2.06M Sell
15,019
-6
-0% -$819 0.01% 442
2023
Q4 		$2.04M Sell
15,025
-996
-6% -$122K 0.01% 412
2023
Q3 		$1.96M Sell
16,021
-920
-5% -$117K 0.01% 386
2023
Q2 		$2.15M Sell
16,941
-3,155
-16% -$410K 0.02% 373
2023
Q1 		$2.6M Sell
20,096
-1,218
-6% -$159K 0.02% 345
2022
Q4 		$2.8M Sell
21,314
-2,179
-9% -$282K 0.02% 326
2022
Q3 		$2.75M Sell
23,493
-777
-3% -$96.5K 0.02% 314
2022
Q2 		$2.85M Buy
24,270
+76
+0.3% +$9.02K 0.02% 313
2022
Q1 		$3.15M Sell
24,194
-319
-1% -$41.6K 0.02% 325
2021
Q4 		$3.74M Buy
24,513
+722
+3% +$112K 0.02% 305
2021
Q3 		$3.85M Buy
23,791
+778
+3% +$131K 0.03% 279
2021
Q2 		$3.77M Buy
+23,013
New +$3.54M 0.03% 247
2021
Q1 		– Sell
-306,929
Closed -$46.5M – 826
2020
Q4 		$46.5M Sell
306,929
-1,576
-0.5% -$225K 0.46% 80
2020
Q3 		$41.8M Buy
308,505
+100,028
+48% +$13.6M 0.47% 84
2020
Q2 		$28.5M Buy
208,477
+189,217
+982% +$24.1M 0.35% 90
2020
Q1 		$2.08M Sell
19,260
-4,488
-19% -$517K 0.03% 215
2019
Q4 		$2.86M Buy
23,748
+663
+3% +$74K 0.03% 221
2019
Q3 		$2.52M Sell
23,085
-611
-3% -$64K 0.03% 218
2019
Q2 		$2.58M Buy
23,696
+545
+2% +$58K 0.03% 214
2019
Q1 		$2.59M Buy
23,151
+370
+2% +$40.6K 0.03% 207
2018
Q4 		$2.2M Sell
22,781
-951
-4% -$101K 0.03% 214
2018
Q3 		$2.89M Sell
23,732
-6,897
-23% -$812K 0.03% 209
2018
Q2 		$3.36M Sell
30,629
-66
-0.2% -$7.06K 0.04% 191
2018
Q1 		$3.28M Sell
30,695
-490
-2% -$54.3K 0.04% 189
2017
Q4 		$3.33M Sell
31,185
-350,571
-92% -$37.5M 0.04% 182
2017
Q3 		$42.5M Sell
381,756
-3,666
-1% -$392K 0.54% 75
2017
Q2 		$39.8M Buy
385,422
+307,779
+396% +$30.3M 0.53% 81
2017
Q1 		$7.56M Buy
77,643
+74,538
+2,401% +$7.14M 0.11% 132
2016
Q4 		$274K Buy
+3,105
New +$283K ﹤0.01% 514
2016
Q3 		– Sell
-3,690
Closed -$317K – 626
2016
Q2 		$317K Buy
3,690
+684
+23% +$61.4K ﹤0.01% 459
2016
Q1 		$261K Sell
3,006
-2,502
-45% -$224K ﹤0.01% 486
2015
Q4 		$621K Buy
5,508
+1,185
+27% +$129K 0.01% 339
2015
Q3 		$437K Sell
4,323
-912
-17% -$109K 0.01% 380
2015
Q2 		$644K Sell
5,235
-33
-0.6% -$3.95K 0.01% 347
2015
Q1 		$603K Buy
5,268
+1,053
+25% +$116K 0.01% 363
2014
Q4 		$426K Sell
4,215
-162
-4% -$15.7K 0.01% 395
2014
Q3 		$399K Sell
4,377
-30
-0.7% -$2.63K 0.01% 395
2014
Q2 		$378K Sell
4,407
-69
-2% -$5.44K 0.01% 421
2014
Q1 		$353K Sell
4,476
-165
-4% -$13.7K 0.01% 428
2013
Q4 		$351K Sell
4,641
-665,349
-99% -$47.2M 0.01% 415
2013
Q3 		$46.8M Sell
669,990
-73,365
-10% -$4.81M 0.97% 29
2013
Q2 		$43.1M Buy
+743,355
New +$43M 0.95% 32

Other funds holding IBB

GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return
FNFDCM
Folger Nolan Fleming Douglas Capital Management Washington, District of Columbia $1.22B AUM 34.81% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
RFA
Reyes Financial Architecture San Diego, California $179M AUM 31.17% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
MCG
McCollum Christoferson Group Amherst, New York $341M AUM 15.01% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Davenport & Co's IBB Position: Q2 2026 in Review

Davenport & Co reduced its iShares Biotechnology ETF (IBB) stake by 7.1% in Q2 2026, selling an estimated $591K and leaving 45,300 shares worth $8.62M. The position accounts for 0.04% of the portfolio, ranked #277.

Davenport & Co first reported a position in IBB in Q2 2013 and has held it in 51 quarters since. The position peaked at $46.8M in Q3 2013. 178 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Davenport & Co held 45,300 shares of iShares Biotechnology ETF worth $8.62M as of Q2 2026.
  • Davenport & Co sold 3,438 iShares Biotechnology ETF shares in Q2 2026, an estimated $591K.
  • iShares Biotechnology ETF made up 0.04% of Davenport & Co's portfolio in Q2 2026, its #277 holding.
  • Davenport & Co first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 51 quarters since.
  • Davenport & Co's iShares Biotechnology ETF position peaked at $46.8M in Q3 2013.
  • 178 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.